Hansa Biopharma Stock

Hansa Biopharma Liabilities 2024

Hansa Biopharma Liabilities

1.19 B SEK

Ticker

HNSA.ST

ISIN

SE0002148817

WKN

A0M65T

In 2024, Hansa Biopharma's total liabilities amounted to 1.19 B SEK, a 9.35% difference from the 1.08 B SEK total liabilities in the previous year.

Hansa Biopharma Aktienanalyse

What does Hansa Biopharma do?

Hansa Biopharma AB is a Swedish biotechnology company specializing in the development of therapy options for rare immune and inflammatory diseases. The company was founded in Lund in 1986 and now has branches in the USA and Japan. The company's business model and divisions include clinical development, corporate development, and production. The clinical development division focuses on conducting clinical studies to demonstrate the effectiveness and safety of new drugs. The corporate development division handles collaboration with regulatory authorities, investors, and other partners. The production division encompasses the manufacturing of products developed by Hansa Biopharma AB. The company's products include Idefirix, an antibody-based drug candidate for the treatment of severe hemolysis due to alloimmune blood group antibodies, and an immunoglobulin production technology platform for the development of antibody therapies for various diseases. Hansa Biopharma AB's roots date back to 1986 when it was established as a spin-off from Lund University. Initially, the company focused on the development and production of diagnostics and reagents for immunology and clinical chemistry. In recent years, it shifted its focus to developing innovative therapies for rare immune and inflammatory diseases. In 2010, the company made a breakthrough with the discovery of the 174H target, which led to the development of Idefirix. Idefirix has since successfully completed phase III clinical trials and may soon be approved for the treatment of severe hemolysis. In conclusion, Hansa Biopharma AB is a leading biotechnology company with a strong vision and clear strategy for developing innovative therapies for rare immune and inflammatory diseases. The company specializes in antibody therapies and is currently focused on the development of Idefirix and the expansion of its immunoglobulin production technology platform. With a strong research pipeline and experienced management team, Hansa Biopharma AB is well-positioned to make significant progress in the coming years and develop innovative therapies for patients with rare diseases. Hansa Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Hansa Biopharma's Liabilities

Hansa Biopharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Hansa Biopharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Hansa Biopharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Hansa Biopharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Hansa Biopharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Hansa Biopharma stock

What is the level of liabilities of Hansa Biopharma this year?

Hansa Biopharma has a debt balance of 1.19 B SEK this year.

What were the liabilities of Hansa Biopharma compared to the previous year?

The liabilities of Hansa Biopharma have increased by 9.35% increased compared to the previous year.

What are the consequences of high debt for investors of Hansa Biopharma?

High liabilities can pose a risk for investors of Hansa Biopharma, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Hansa Biopharma?

Low liabilities mean that Hansa Biopharma has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Hansa Biopharma affect the company?

An increase in liabilities of Hansa Biopharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Hansa Biopharma affect the company?

A decrease in the liabilities of Hansa Biopharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Hansa Biopharma?

Some factors that can influence the liabilities of Hansa Biopharma include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Hansa Biopharma so important for investors?

The liabilities of Hansa Biopharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Hansa Biopharma take to modify the liabilities?

To change its liabilities, Hansa Biopharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Hansa Biopharma pay?

Over the past 12 months, Hansa Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hansa Biopharma is expected to pay a dividend of 0 SEK.

What is the dividend yield of Hansa Biopharma?

The current dividend yield of Hansa Biopharma is .

When does Hansa Biopharma pay dividends?

Hansa Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hansa Biopharma?

Hansa Biopharma paid dividends every year for the past 0 years.

What is the dividend of Hansa Biopharma?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hansa Biopharma located?

Hansa Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hansa Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hansa Biopharma from 11/1/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Hansa Biopharma pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Hansa Biopharma in the year 2023?

In the year 2023, Hansa Biopharma distributed 0 SEK as dividends.

In which currency does Hansa Biopharma pay out the dividend?

The dividends of Hansa Biopharma are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hansa Biopharma

Our stock analysis for Hansa Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hansa Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.